Provider Briefing: Invokamet Availability in 2026

If your patients are reporting difficulty filling their Invokamet (Canagliflozin/Metformin) prescriptions, they're not imagining things. While Invokamet is not on the FDA's formal drug shortage list as of early 2026, real-world access barriers are creating a functional availability gap for many patients.

This briefing covers the current supply landscape, prescribing considerations, cost and insurance dynamics, and practical tools to help your patients maintain uninterrupted therapy.

Timeline and Background

Invokamet was FDA-approved in August 2014 as a fixed-dose combination of Canagliflozin (an SGLT2 inhibitor) and Metformin Hydrochloride (a biguanide). An extended-release formulation, Invokamet XR, followed in 2016. Both are manufactured exclusively by Janssen Pharmaceuticals (Johnson & Johnson).

Key timeline events:

• 2014: FDA approval of Invokamet (immediate-release)
• 2016: FDA approval of Invokamet XR (extended-release)
• 2017: FDA added boxed warning for lower limb amputation risk (Canagliflozin component)
• 2020: FDA updated labeling to include lactic acidosis boxed warning and lower limb amputation warning
• 2020: Metformin (generic) shortages due to NDMA contamination recalls across multiple manufacturers
• 2026: No formal shortage listed; generic entry estimated ~2029

Prescribing Implications

Boxed Warnings

Invokamet carries two boxed warnings that may influence prescribing decisions:

1. Lactic Acidosis (Metformin component): Rare but potentially fatal. Contraindicated in patients with eGFR <30 mL/min/1.73 m². Obtain renal function before initiating and periodically thereafter. Hold before and 48 hours after iodinated contrast procedures.
2. Lower Limb Amputation (Canagliflozin component): Approximately 2-fold increased risk observed in clinical trials, primarily toe and midfoot amputations. Assess risk factors before initiating — peripheral vascular disease, neuropathy, prior amputation, and diabetic foot ulcers.

Notably, alternative SGLT2 inhibitors Empagliflozin (Jardiance/Synjardy) and Dapagliflozin (Farxiga/Xigduo XR) do not carry the amputation boxed warning.

Renal Dosing Considerations

• eGFR ≥60: Full dosing range available (Canagliflozin up to 300 mg/day)
• eGFR 45-59: Limit Canagliflozin to 100 mg/day
• eGFR 30-44: Do not initiate; may continue 100 mg/day if already tolerating
• eGFR <30: Contraindicated (both components)

Drug Interactions of Clinical Significance

• UGT enzyme inducers (Rifampin, Phenytoin, Phenobarbital, Ritonavir): Decrease Canagliflozin exposure. Consider dose increase to 300 mg/day if coadministration is necessary.
• Digoxin: Canagliflozin increases Digoxin AUC by ~20%. Monitor Digoxin levels.
• Carbonic anhydrase inhibitors (Topiramate, Zonisamide): Increased lactic acidosis risk.
• Insulin/sulfonylureas: Increased hypoglycemia risk. Consider dose reduction of insulin or secretagogues when initiating Invokamet.

For a comprehensive interactions reference, see our Invokamet drug interactions guide.

Current Availability Picture

As of March 2026, Invokamet is in continuous production by Janssen. The practical availability challenges are driven by:

• Single-source manufacturing: No generic competitors until ~2029. Only one manufacturer means any production disruption could create real shortages.
• Pharmacy inventory economics: At $575–$800 wholesale per month's supply, many retail pharmacies limit inventory to patient-specific orders.
• Formulary positioning: Invokamet is classified as non-preferred brand on many commercial and Medicare Part D formularies, with prior authorization or step therapy requirements. Some PBMs prefer Synjardy or Xigduo XR.
• Strength fragmentation: Eight SKUs across IR and XR formulations (4 strengths × 2 release types) spread available inventory thin.

Cost and Access Dynamics

Understanding the cost landscape helps when counseling patients:

• AWP/retail: $575–$800/month (30-day supply)
• GoodRx coupon: ~$576–$595/month
• Janssen CarePath Savings Card: $0/month for eligible commercially insured patients (annual maximum applies)
• Medicare Part D: Covered by most plans; copays vary widely ($50–$200+/month depending on plan tier and coverage phase)
• Patient Assistance (JJPAF): Free medication for qualifying uninsured/underinsured patients via Johnson & Johnson Patient Assistance Foundation (1-800-652-6227 or jjpaf.org)

Insurance Navigation Tips

• If prior authorization is denied, Janssen offers appeal support through their CarePath program
• For Medicare patients in the coverage gap, manufacturer coupons are not applicable — explore JJPAF or therapeutic alternatives
• Step therapy typically requires documented trial and failure of Metformin monotherapy ± another oral agent

Tools and Resources for Your Practice

• Medfinder for Providers: Help patients locate Invokamet in stock at pharmacies near them. Recommend this tool during office visits when prescribing brand-name medications with variable availability.
• Janssen CarePath: Enroll patients in the savings program during the prescribing encounter. Forms available at invokanahcp.com.
• Electronic prior authorization (ePA): If your EHR supports ePA, submit prior authorization at the point of prescribing to reduce fill delays.
• Mail-order pharmacy: Recommend patients check their insurance's mail-order benefit for 90-day supplies, which reduces the frequency of stock-out encounters.

Therapeutic Alternatives for Consideration

When Invokamet is unavailable or inappropriate, consider these alternatives:

1. Synjardy/Synjardy XR (Empagliflozin/Metformin) — Strong cardiovascular outcome data (EMPA-REG OUTCOME). No amputation boxed warning.
2. Xigduo XR (Dapagliflozin/Metformin ER) — Once-daily dosing. Dapagliflozin has additional HF and CKD indications (DAPA-HF, DAPA-CKD).
3. Segluromet (Ertugliflozin/Metformin) — Less robust CV outcome data (VERTIS CV). May have formulary advantages on certain plans.
4. Separate components — Invokana (Canagliflozin) + generic Metformin. Preserves same pharmacology with more dosing flexibility. Generic Metformin widely available at $4–$20/month.

For a patient-facing comparison, see our Invokamet alternatives guide.

Looking Ahead

Generic Invokamet is anticipated around 2029 based on current patent expirations. Until then:

• Monitor formulary changes during annual open enrollment — Invokamet's tier status may shift
• The CREDENCE trial data supporting Canagliflozin for diabetic kidney disease may influence future formulary positioning
• Consider proactive switches to Empagliflozin- or Dapagliflozin-based combinations for patients with amputation risk factors

Final Thoughts

While Invokamet is not in a formal shortage, the combination of single-source manufacturing, high cost, and insurance barriers creates meaningful access challenges for patients. Proactive prescribing strategies — including copay assistance enrollment, ePA submission, and backup plans for therapeutic substitution — can help ensure your patients maintain glycemic control without gaps in therapy.

Visit Medfinder for Providers for real-time pharmacy availability data that you can share with patients at the point of care.